Biomonitoring equivalents for hexachlorobenzene

Regulatory Toxicology and Pharmacology

Volumn 58, Issue 1, 2010, Pages 25-32

  Aylward, Lesa L ^a   Hays, Sean M ^a   Gagné, Michelle ^b   Nong, Andy ^c   Krishnan, Kannan ^b  

^a LLP   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HEALTH CANADA   (Canada)

Author keywords

Biomonitoring Equivalents; Hexachlorobenzene; Pharmacokinetics; Risk assessment

Indexed keywords

BIOLOGICAL MARKER; HEXACHLOROBENZENE; LIPID;

ARTICLE; BIOASSAY; BIOLOGICAL MONITORING; CANCER RISK; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; LIPID BLOOD LEVEL; LIVER LEVEL; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; STANDARDIZATION; TISSUE DISTRIBUTION; TISSUE LEVEL; TOXICOKINETICS;

ANIMALS; BIOLOGICAL MARKERS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; ENVIRONMENTAL POLLUTION; FEMALE; FUNGICIDES, INDUSTRIAL; HEXACHLOROBENZENE; HUMANS; MALE; RATS; REFERENCE VALUES; RISK ASSESSMENT;

RODENTIA;

EID: 77955925441     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.06.003     Document Type: Article

References (38)

1. Agency for Toxic Substances and Disease Registry (ATSDR), 2002. Toxicological Profile for Hexachlorobenzene. PB2003-100139. <> (accessed 16.11.09). http://www.atsdr.cdc.gov/toxprofiles/tp90.html.
2. Arnold D.L., Moodie C.A., Charbonneau S.M., Grice H.C., McGuire P.F., Bryce F.R., Collins B.T., Zawidzka Z.Z., Krewski D.R., Nera E.A., Munro I.C. Long-term toxicity of hexachlorobenzene in the rat and the effect of dietary vitamin A. Food Chem. Toxicol. 1985, 23:779-793.
3. Arnold D.L., Moodie C.A., Collins B.T., Zawidzka Z.Z., Krewski D.R. Two-generation chronic toxicity study with hexachlorobenzene in the rat. IARC Sci. Publ. 1986, 77:405-410.
4. Centers for Disease Control and Prevention (CDC), 2009. Fourth National Report on Human Exposure to Environmental Chemicals. Department of Health and Human Services. Atlanta, GA. Available from:<> (accessed 05.01.10). http://www.cdc.gov/exposurereport/.
5. Courtney K.D., Andrews J.E., Svendsgaard D.J. Hexachlorobenzene (HCB) deposition in maternal and fetal tissues of rat and mouse. I. Chemical quantification of HCB in tissues. Environ. Res. 1979, 19:1-13.
6. den Besten C., Bennik M.H., Bruggeman I., Schielen P., Kuper F., Brouwer A., Koeman J.H., Vos J.G., Van Bladeren P.J. The role of oxidative metabolism in hexachlorobenzene-induced porphyria and thyroid hormone homeostasis: a comparison with pentachlorobenzene in a 13-week feeding study. Toxicol. Appl. Pharmacol. 1993, 119:181-194.
7. den Besten C., Bennik M.M., van Iersel M., Peters M.A., Teunis C., Van Bladeren P.J. Comparison of the urinary metabolite profiles of hexachlorobenzene and pentachlorobenzene in the rat. Chem. Biol. Interact. 1994, 90:121-137.
8. Dewailly E., Mulvad G., Pedersen H.S., Ayotte P., Demers A., Weber J.P., Hansen J.C. Concentration of organochlorines in human brain, liver, and adipose tissue autopsy samples from Greenland. Environ. Health Perspect. 1999, 107:823-828.
9. Erturk E., Lambrecht R.W., Peters H.A., Cripps D.J., Gocmen A., Morris C.R., Bryan G.T. Oncogenicity of hexachlorobenzene. IARC Sci. Publ. 1986, 77:417-423.
10. Freeman R.A., Rozman K.K., Wilson A.G. Physiological pharmacokinetic model of hexachlorobenzene in the rat. Health Phys. 1989, 57(Suppl. 1):139-145. discussion 145-147.
11. Funck-Brentano C., Boelle P.Y., Verstuyft C., Bornert C., Becquemont L., Poirier J.M. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur. J. Clin. Pharmacol. 2005, 61:821-829.
12. Glynn A., Aune M., Nilsson I., Darnerud P.O., Ankarberg E.H., Bignert A., Nordlander I. Declining levels of PCB, HCB and p,p'-DDE in adipose tissue from food producing bovines and swine in Sweden 1991-2004. Chemosphere 2009, 74:1457-1462.
13. Hays S.M., Aylward L.L. Using biomonitoring equivalents to interpret human biomonitoring data in a public health risk context. J. Appl. Toxicol. 2009, 29:275-288.
14. Hays S.M., Becker R.A., Leung H.W., Aylward L.L., Pyatt D.W. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regul. Toxicol. Pharmacol. 2007, 47:96-109.
15. Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk C., DiZio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W. Guidelines for the derivation of biomonitoring equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul. Toxicol. Pharmacol. 2008, 51:S4-S15.
16. Heath Canada, 1993. Priority Substances List Assessment Report: Hexachlorobenzene. <> (accessed 16.11.09). http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/psl1-lsp1/hexachlorobenzene/index-eng.php.
17. International Programme for Chemical Safety (IPCS), 1997. Hexachlorobenzene (Environmental Health Criteria 195). World Health Organization, Geneva, Switzerland. <> (accessed 16.11.09). http://www.inchem.org/documents/hsg/hsg/hsg107.htm.
18. Koss G., Koransky W. Studies on the toxicology of hexachlorobenzene. I. Pharmacokinetics. Arch. Toxicol. 1975, 34:203-212.
19. Koss G., Seubert S., Seubert A., Koransky W., Ippen H. Studies on the toxicology of hexachlorobenzene. III. Observations in a long-term experiment. Arch. Toxicol. 1978, 40:285-294.
20. Koss, G., Reuter, A., Koransky, W., 1986. Excretion of metabolites of hexachlorobenzene in the rat and in man. IARC Sci. Publ., 261-266.
21. Kuiper-Goodman T., Grant D.L., Moodie C.A., Korsrud G.O., Munro I.C. Subacute toxicity of hexachlorobenzene in the rat. Toxicol. Appl. Pharmacol. 1977, 40:529-549.
22. LaKind J.S., Aylward L.L., Brunk C., DiZio S., Dourson M., Goldstein D.A., Kilpatrick M.E., Krewski D., Bartels M.J., Barton H.A., Boogaard P.J., Lipscomb J., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W., Hays S.M. Guidelines for the communication of biomonitoring equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul. Toxicol. Pharmacol. 2008, 51:S16-S26.
23. Lu Y., Lohitnavy M., Reddy M.B., Lohitnavy O., Ashley A., Yang R.S. An updated physiologically based pharmacokinetic model for hexachlorobenzene: incorporation of pathophysiological states following partial hepatectomy and hexachlorobenzene treatment. Toxicol. Sci. 2006, 91:29-41.
24. Minh T.B., Watanabe M., Tanabe S., Yamada T., Hata J., Watanabe S. Specific accumulation and elimination kinetics of tris(4-chlorophenyl)methane, tris(4-chlorophenyl)methanol, and other persistent organochlorines in humans from Japan. Environ. Health Perspect. 2001, 109:927-935.
25. Pelekis M., Poulin P., Krishnan K. An approach for incorporating tissue composition into physiologically based pharmacokinetic models. Toxicol. Ind. Health 1995, 11:511-522.
26. Petersen M.S., Halling J., Damkier P., Nielsen F., Grandjean P., Weihe P., Brosen K. Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. Toxicol. Appl. Pharmacol. 2007, 224:202-206.
27. Phillips D.L., Pirkle J.L., Burse V.W., Bernert J.T., Henderson L.O., Needham L.L. Chlorinated hydrocarbon levels in human serum: effects of fasting and feeding. Arch. Environ. Contam. Toxicol. 1989, 18:495-500.
28. Poulin P., Krishnan K. An algorithm for predicting tissue:blood partition coefficients of organic chemicals from n-octanol:water partition coefficient data. J. Toxicol. Environ. Health 1995, 46:117-129.
29. Reed L., Buchner V., Tchounwou P.B. Environmental toxicology and health effects associated with hexachlorobenzene exposure. Rev. Environ. Health. 2007, 22:213-243.
30. Schielen P., Den Besten C., Vos J.G., Van Bladeren P.J., Seinen W., Bloksma N. Immune effects of hexachlorobenzene in the rat: role of metabolism in a 13-week feeding study. Toxicol. Appl. Pharmacol. 1995, 131:37-43.
31. Sundlof S.F., Hansen L.G., Koritz G.D., Sundlof S.M. The pharmacokinetics of hexachlorobenzene in male beagles. Distribution, excretion, and pharmacokinetic model. Drug Metab. Dispos. 1982, 10:371-381.
32. To-Figueras J., Sala M., Otero R., Barrot C., Santiago-Silva M., Rodamilans M., Herrero C., Grimalt J., Sunyer J. Metabolism of hexachlorobenzene in humans: association between serum levels and urinary metabolites in a highly exposed population. Environ. Health Perspect. 1997, 105:78-83.
33. To-Figueras J., Barrot C., Sala M., Otero R., Silva M., Ozalla M.D., Herrero C., Corbella J., Grimalt J., Sunyer J. Excretion of hexachlorobenzene and metabolites in feces in a highly exposed human population. Environ. Health Perspect. 2000, 108:595-598.
34. United States Environmental Protection Agency (US EPA), 1996. Hexachlorobenzene. Integrated Risk Information System. (accessed 16.11.09). http://www.epa.gov/NCEA/iris/subst/0374.htm.
35. Verner M.A., Charbonneau M., Lopez-Carrillo L., Haddad S. Physiologically based pharmacokinetic modeling of persistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studies. Environ. Health Perspect. 2008, 116:886-892.
36. Weistrand C., Noren K. Polychlorinated naphthalenes and other organochlorine contaminants in human adipose and liver tissue. J. Toxicol. Environ. Health A 1998, 53:293-311.
37. Yang R.S., Pittman K.A., Rourke D.R., Stein V.B. Pharmacokinetics and metabolism of hexachlorobenzene in the rat and the rhesus monkey. J. Agric. Food Chem. 1978, 26:1076-1083.
38. Yesair, D.W., Feder, P.I., Chin, A.E., Naber, S.J., Kuiper-Goodman, T., Scott, C.S., Robinson, P.E., 1986. Development, evaluation and use of a pharmacokinetic model for hexachlorobenzene. IARC Sci. Publ., 297-318.